UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 130

Sortiert nach

Target profiling of small molecules by chemical proteomics

Nature Chemical Biology, 2009-09, Vol.5 (9), p.616-624

2009

Volltextzugriff (PDF)

An immunoproteomic approach to characterize the CAR interactome and signalosome

Science signaling, 2019-02, Vol.12 (568)

2019

Volltextzugriff (PDF)

Off-target based drug repurposing opportunities for tivantinib in acute myeloid leukemia

Scientific reports, 2019-01, Vol.9 (1), p.606-606, Article 606

2019

Volltextzugriff (PDF)

Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets

Blood, 2007-12, Vol.110 (12), p.4055-4063

2007

Volltextzugriff (PDF)

IGF-binding proteins secreted by cancer-associated fibroblasts induce context-dependent drug sensitization of lung cancer cells

Science signaling, 2022-08, Vol.15 (747), p.eabj5879

2022

Volltextzugriff (PDF)

EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13), p.3551-3563

2017

Volltextzugriff (PDF)

Proteome-wide Profiling of Clinical PARP Inhibitors Reveals Compound-Specific Secondary Targets

Cell chemical biology, 2016-12, Vol.23 (12), p.1490-1503

2016

Volltextzugriff (PDF)

Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib

Leukemia & lymphoma, 2008-04, Vol.49 (4), p.615-619

2008

Volltextzugriff (PDF)

Chemoproteomics Reveals Novel Protein and Lipid Kinase Targets of Clinical CDK4/6 Inhibitors in Lung Cancer

ACS chemical biology, 2015-12, Vol.10 (12), p.2680-2686

2015

Volltextzugriff (PDF)

Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells

Proceedings of the National Academy of Sciences - PNAS, 2013-07, Vol.110 (30), p.12414-12419

2013

Volltextzugriff (PDF)

Dual Targeting of WEE1 and PLK1 by AZD1775 Elicits Single Agent Cellular Anticancer Activity

ACS chemical biology, 2017-07, Vol.12 (7), p.1883-1892

2017

Volltextzugriff (PDF)

A chemical and phosphoproteomic characterization of dasatinib action in lung cancer

Nature chemical biology, 2010-04, Vol.6 (4), p.291

2010

Volltextzugriff (PDF)

Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib

Proceedings of the National Academy of Sciences - PNAS, 2007-08, Vol.104 (33), p.13283-13288

2007

Volltextzugriff (PDF)

GSK3 Alpha and Beta Are New Functionally Relevant Targets of Tivantinib in Lung Cancer Cells

ACS chemical biology, 2014-02, Vol.9 (2), p.353-358

2014

Volltextzugriff (PDF)

Nanoscalic silver possesses broad-spectrum antimicrobial activities and exhibits fewer toxicological side effects than silver sulfadiazine

Nanomedicine, 2012-05, Vol.8 (4), p.478-488

2012

Volltextzugriff (PDF)

Dabrafenib inhibits the growth of BRAF‐WT cancers through CDK16 and NEK9 inhibition

Molecular oncology, 2018-01, Vol.12 (1), p.74-88

2018

Volltextzugriff (PDF)

CDK4/6 inhibition synergizes with inhibition of P21-Activated Kinases (PAKs) in lung cancer cell lines

PloS one, 2021-06, Vol.16 (6), p.e0252927-e0252927

2021

Volltextzugriff (PDF)

Cell Type–specific Adaptive Signaling Responses to KRASG12C Inhibition

Clinical cancer research, 2021-05, Vol.27 (9), p.2533-2548

2021

Volltextzugriff (PDF)

Ceritinib Enhances the Efficacy of Trametinib in BRAF/NRAS -Wild-Type Melanoma Cell Lines

Molecular cancer therapeutics, 2018-01, Vol.17 (1), p.73-83

2018

Volltextzugriff (PDF)

PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer

Molecular cancer therapeutics, 2016-07, Vol.15 (7), p.1669-1681

2016

Volltextzugriff (PDF)

Modification of post-PKS tailoring steps through combinatorial biosynthesis

Natural product reports, 2002-10, Vol.19 (5), p.542-580

2002

Volltextzugriff (PDF)

KIT-D816V–independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib

Blood, 2011-08, Vol.118 (7), p.1885-1898

2011

Volltextzugriff (PDF)

Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms

Molecular systems biology, 2013-11, Vol.9 (1), p.705-n/a

2013

Volltextzugriff (PDF)

Characterization of epidermal growth factor receptor (EGFR) P848L, an unusual EGFR variant present in lung cancer patients, in a murine Ba/F3 model

FEBS open bio, 2019-10, Vol.9 (10), p.1689-1704

2019

Volltextzugriff (PDF)

Identification of kinase inhibitor targets in the lung cancer microenvironment by chemical and phosphoproteomics

Molecular cancer therapeutics, 2014-11, Vol.13 (11), p.2751-2762

2014

Volltextzugriff (PDF)

1 – 25 von 130

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(120)
Mit Volltextzugriff
(119)

Publikationsform

Sprache

Englisch
(130)
Japanisch
(30)

Erscheinungsjahr

n.n

Thema

Science & Technology
(77)
Life Sciences & Biomedicine
(69)
Humans
(54)
Biochemistry & Molecular Biology
(36)
Cell Line, Tumor
(32)
Animals
(25)
Proteomics
(25)
Oncology
(24)
Protein Kinase Inhibitors - Pharmacology
(24)
Mice
(19)
Mutation
(17)
Kinases
(16)
Proteins
(16)
Pyrimidines - Pharmacology
(15)
Antineoplastic Agents - Pharmacology
(14)
Lung Neoplasms - Drug Therapy
(14)
Dasatinib
(13)
Female
(13)
Biochemical Research Methods
(12)
Lung Cancer
(12)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Target profiling of small molecules by chemical proteomics

An immunoproteomic approach to characterize the CAR interactome and signalosome

Off-target based drug repurposing opportunities for tivantinib in acute myeloid leukemia

Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets

IGF-binding proteins secreted by cancer-associated fibroblasts induce context-dependent drug sensitization of lung cancer cells

EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases

Proteome-wide Profiling of Clinical PARP Inhibitors Reveals Compound-Specific Secondary Targets

Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib

Chemoproteomics Reveals Novel Protein and Lipid Kinase Targets of Clinical CDK4/6 Inhibitors in Lung Cancer

Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells

Dual Targeting of WEE1 and PLK1 by AZD1775 Elicits Single Agent Cellular Anticancer Activity

A chemical and phosphoproteomic characterization of dasatinib action in lung cancer

Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib

GSK3 Alpha and Beta Are New Functionally Relevant Targets of Tivantinib in Lung Cancer Cells

Nanoscalic silver possesses broad-spectrum antimicrobial activities and exhibits fewer toxicological side effects than silver sulfadiazine

Dabrafenib inhibits the growth of BRAF‐WT cancers through CDK16 and NEK9 inhibition

CDK4/6 inhibition synergizes with inhibition of P21-Activated Kinases (PAKs) in lung cancer cell lines

Cell Type–specific Adaptive Signaling Responses to KRASG12C Inhibition

Ceritinib Enhances the Efficacy of Trametinib in BRAF/NRAS -Wild-Type Melanoma Cell Lines

PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer

Modification of post-PKS tailoring steps through combinatorial biosynthesis

KIT-D816V–independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib

Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms

Characterization of epidermal growth factor receptor (EGFR) P848L, an unusual EGFR variant present in lung cancer patients, in a murine Ba/F3 model

Identification of kinase inhibitor targets in the lung cancer microenvironment by chemical and phosphoproteomics

Suchergebnisse filtern